GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LP-352 overview

LP-352 (AN-352) is under development for the treatment of developmental and epileptic encephalopathies (DEEs) refractory focal epilepsies, Lennox-Gastaut Syndrome, dravet syndrome, tuberous sclerosis complex and CDKL5 deficiency disorder. It is administered by oral route. The drug candidate is developed based on arena neuroscience platform. It acts by targeting 5-Hydroxytryptamine Receptor 2C.

Longboard Pharmaceuticals overview

Longboard Pharmaceuticals (Longboard) is a clinical-stage biopharmaceutical company that discover and develops novel, transformative medicines for neurological diseases. The company’s pipeline program includes LP352, an oral 5-HT2c super agonist targeting dravet syndrome, lennox-gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder, and other epileptic disorders; LP143, a CB2 agonist against amyotrophic lateral sclerosis (ALS) and neuroinflammatory disorders; and LP659, S1P receptor modulator targeting multiple neuroinflammatory disorders. It is also developing medicines for the treatment of central nervous system neuroinflammatory diseases and epileptic encephalopathies. Longboard is headquartered in La Jolla, California, the US

For a complete picture of LP-352’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.